Systemic oxidative stress and antioxidant capacity in cancer patients by Leimkühler, Maleen et al.
  
 University of Groningen
Systemic oxidative stress and antioxidant capacity in cancer patients
Leimkühler, Maleen; Bourgonje, Arno R.; van Goor, Harry; van Leeuwen, Barbara L.; de
Bock, Geertruida H.
Published in:
Journal of Translational Science
DOI:
10.15761/JTS.1000372
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Leimkühler, M., Bourgonje, A. R., van Goor, H., van Leeuwen, B. L., & de Bock, G. H. (2020). Systemic
oxidative stress and antioxidant capacity in cancer patients. Journal of Translational Science, 6, [372].
https://doi.org/10.15761/JTS.1000372
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 19-05-2020
Mini Review
Journal of Translational Science
J Transl Sci, 2020         doi: 10.15761/JTS.1000372  Volume 6: 1-3
ISSN: 2059-268X
Systemic oxidative stress and antioxidant capacity in cancer 
patients
Leimkuhler M1, Bourgonje AR2, van Goor H3, van Leeuwen BL1 and Bock de GH4*
1Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ Groningen, 
The Netherlands
3Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ Groningen, 
The Netherlands
4Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Abstract
Various factors impact the outcome of patients with the diagnosis of cancer. Common treatment modalities of cancer, including surgery, radiation therapy and 
cytostatic agents, all lead to a systemic inflammatory reaction. In particular, this reaction is of physiological importance as it is crucial for patient recovery. However, in 
some patients, a self-perpetuating inflammatory response develops due to the presence of unfavorable risk factors, several of which are still unknown, but might lead to 
a worse disease prognosis. Inflammation has been intimately associated with oxidative stress, that is characterized by an imbalance between pro-oxidants, also termed 
reactive species, and antioxidants. Systemically, oxidative stress can be quantified by measuring thiols (R-SH, sulfhydryl compounds), which are considered to be 
regulatory nodes within the extracellular antioxidant network. Most importantly, thiol measurements in serum or plasma form a robust and powerful read-out of the 
in vivo reduction-oxidation (redox) status as thiols are highly redox-active and thus readily oxidized by circulating reactive species. Therefore, systemic quantification 
of thiols might be a valuable addition to the clinically available diagnostic and prognostic armamentarium as it is able to reliably capture the overall balance between 
oxidants and the antioxidant capacity of patients. In this review, we summarized the currently available literature on thiol levels as amendable markers for oxidative 
stress in patients with lung, prostate and colorectal cancer. Total thiols, native (free) thiols and disulfide levels are significantly altered in these patients compared to 
healthy individuals. In general, these findings indicate that the extracellular antioxidant capacity is severely affected in patients with these types of cancer. Moreover, 
lower thiol levels are associated with a lowered overall survival. Future research should focus on exploration of the clinical significance of thiols in cancer.
Introduction
Over the past decades, the outcome of various cancer treatments 
has improved in terms of overall and disease-free survival. However, 
treatment is often intensive and might lead to (severe) complications 
and a diminished quality of life for the patient. Though essential for 
patient recovery, an exaggerated systemic inflammatory response is 
associated with the occurrence of complications after cancer treatment 
[1,2]. Systemic inflammation is intimately associated with oxidative 
stress [1]. Oxidative stress is characterized by an excessive production of 
reactive species and decreased availability of antioxidants, also referred 
to as a redox imbalance [3-6]. A redox imbalance becomes apparent 
when the antioxidant capacity of the patient is decreased. [1,2,5,7]. 
Increased levels of oxidative stress have been suggested to be related to 
oncogenic stimulation, such as uncontrolled cell proliferation and DNA 
or protein modification [3,5,7,8].
Thiols (R-SH, sulfhydryl compounds) are central to the 
extracellular non-enzymatic antioxidant capacity, and can be easily 
measured in patients’ serum or plasma using established colorimetric 
detection methods [9,10]. Generally, thiols are considered as a 
robust and powerful read-out of an individual’s systemic reduction-
oxidation (redox) status as they are rapidly oxidized by nearby reactive 
species [5,7,11,12]. Thus, systemic oxidative stress is associated with 
reduced levels of thiols, whereas higher levels of thiols are considered 
representative of a more favorable redox status in vivo [13]. Thiols are 
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characterized by sulfhydryl groups (-SH), which are responsible for 
their potent antioxidant activity, and can be oxidized by reactive species 
to form reversible disulfide compounds (RSSR’), a dynamic equilibrium 
which is commonly termed thiol-disulfide homeostasis, as illustrated 
in Figure 1 [7,14-16]. The plasma thiol pool mainly consists of albumin 
and protein thiols, while the remainder is composed by low-molecular-
weight (LMW) thiols (e.g. cysteine or glutathione) [11]. Thiol-disulfide 
homeostasis is a dynamic physiological entity representing the net result 
of kinetically controlled intra- and extracellular exchange reactions 
and has important functions in different cellular processes, such as 
proliferation, inflammation and apoptosis [3,8,11,15,17]. Systemic 
oxidative stress is reflected by decreased levels of reduced (free) thiols 
(native thiols) and total thiols, and increased levels of disulfides [18]. A 
reduced antioxidant capacity has been demonstrated in various types of 
cancers [19]. Measuring the antioxidant capacity, therefore, can provide 
us with valuable information about the redox status of cancer patients 
and their buffering capability to counterbalance oxidative stress. To 
know the response of thiol levels to various treatments and their clinical 
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implications might help to improve risk stratification of cancer patients. 
In this review, we summarize the currently available literature on thiol 
redox status specifically in patients with lung, prostate and colorectal 
cancer. In addition, we describe how systemic thiol levels are related 
to patient outcomes. For that, in collaboration with an experienced 
medical research librarian, a search strategy was developed and a 
search was performed in PubMed (Supplementary 1, date of search: 
16/01/2020). Available literature was screened on title and in case 
of potential relevance, the abstract was screened. Ten publications 
were included in this review. Thiol redox status in lung, prostate and 
colorectal cancer
Lung cancer 
Three studies described the thiol redox status in patients affected by 
lung cancer (Table 1). All of these studies found total thiol levels, and 
two studies found native thiol levels and disulfide levels to be reduced 
in lung cancer patients compared to healthy controls [5,19,20]. These 
results indicate that the extracellular antioxidant capacity is generally 
compromised in these patients. In addition, one study described that 
total thiol levels were associated with ageing and a history of smoking 
[19], whereas another study described that current smoking, COPD, 
the histological subtypes of the tumor or arterial hypertension were not 
associated with thiol/disulfide homeostasis in this patient group [20], 
although this might be the result of a lack of statistical power. Patients 
with lower total thiol levels showed a significantly lower Karnofsky 
performance score [5]. In addition, patients with lower native thiol 
levels or disulfide levels showed a decreased overall survival [5,20]. 
Prostate cancer
Five studies reported on the thiol redox status in patients 
with prostate cancer [8,17,19,21,22]. All, but one [21], described 
significantly lower levels of total thiols in patients with prostate cancer 
compared to healthy controls, and three described lower native thiol 
levels [8,17,22], but only two studies also described lower disulfide 
levels [8,22]. Factors that were associated with lower thiol levels in 
prostate cancer constituted older age, lower educational level, current 
or previous smoking and a higher BMI [19]. Interestingly, in one study, 
it was demonstrated that native and total thiol levels were increased six 
months after prostatectomy [8], suggesting that higher thiol levels are 
influenced by tumor presence. 
Colorectal cancer
In patients with colorectal cancer, total thiol levels were lowered 
compared to healthy subjects [19], as well as the disulfide level [14]. In 
patients with more aggressive tumors, the disulfide level was even lower 
than in patients with slow growing tumors [14]. In addition, lower thiol 
levels were associated with a higher age and a higher BMI [19]. 
Conclusion and general discussion
In general, the extracellular non-enzymatic antioxidant capacity, 
as reflected by the level of thiols, is significantly compromised in 
patients with lung cancer, prostate cancer or colorectal cancer. The 
same phenomenon has been described for other tumor types as well 
[14,19,23,24]. Lower thiol levels have also been associated with a 
reduced overall survival in patients with oral squamous carcinoma 
[24]. Similar results were seen in patients with multiple myeloma, 
where treated patients presented with lower thiol levels than patients 
who were about to initiate treatment [25]. In addition, lower thiol levels 
might have a prognostic value in the development of chemotherapy-
induced cardiac toxicity [15]. It has previously been observed that total 
thiol levels, native thiol levels and disulfide levels are decreased after a Figure 1. Thiol-disulfide homeostasis
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Table 1. Available data on thiol and disulfide levels in cancer patients and healthy controls (˟median (range); na=not available; *measurements out of graph)
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prostate biopsy [26], but it is unknown whether this has any prognostic 
significance. These results might lead to the assumption that patients 
should be treated with antioxidants to improve their prognosis. In the 
past, researchers focused on antioxidant therapy to improve disease 
prognosis, however, results from these studies were disappointingly 
unsuccessful. For example, it was found that long-term supplementation 
with antioxidants can even lead to a promotion of metastasis, as shown 
in a mouse model of vitamin E effects on lung cancer metastasis [27]. 
This might be the consequence of the complexity of the redox system, 
which in general serves a physiological purpose and is only harmful in 
the situation of overproduction of reactive species. Therefore, targeted 
therapeutic modulation, taking into account patient comorbidity and 
varying phenotypes of each patient, might be crucial in order to achieve 
successful therapy.
Measurement of serum or plasma thiols and the determination of 
thiol/disulfide homeostasis may be a valuable strategy to determine 
the systemic redox status of an individual patient [28]. However, thiol 
levels can be influenced by a multitude of factors and are not disease-
specific. In addition, the studies discussed in this review have been 
performed in highly selected patients and control groups, without 
various comorbidities that influence systemic thiol levels [8,22]. 
This might overestimate the influence of thiols on the prognosis, as 
results are not generalizable to the general population of patients. In 
the future, prospective, longitudinal studies are required, that focus 
on the response of thiol-based redox signaling to various treatments 
and its clinical implications. Furthermore, studies should focus on 
further unraveling the redox system and its association with individual 
characteristics, such as genes, proteins or the gut microbiome, to 
disclose major determinants of the redox system.
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